Is Personalized Medicine Here?

Benedito A. Carneiro, Ricardo Costa, Timothy Taxter, Sunandana Chandra, Young K wang Chae, Massimo Cristofanilli, Francis J. Giles

Research output: Contribution to journalReview article

Abstract

Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of cancer genomics is reshaping the drug development process, from drug discovery to novel designs of clinical trials. It is also exposing the critical importance of rigorous validation of molecular diagnostics platforms, such as the use of whole-exome sequencing and patient-derived xenografts, which may eventually be utilized to guide treatment decisions and may ultimately enable the true practice of personalized oncology. This review describes the achievements in therapeutic and molecular diagnostics, details evolving molecular platforms, and highlights the challenges for the translation of these developments to daily clinical practice.

Original languageEnglish (US)
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number4
StatePublished - Apr 1 2016

Fingerprint

Precision Medicine
Molecular Pathology
Genomics
Exome
Neoplasms
Drug Discovery
Heterografts
Therapeutics
Clinical Trials
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Carneiro, B. A., Costa, R., Taxter, T., Chandra, S., Chae, Y. K. W., Cristofanilli, M., & Giles, F. J. (2016). Is Personalized Medicine Here? Oncology (Williston Park, N.Y.), 30(4).
Carneiro, Benedito A. ; Costa, Ricardo ; Taxter, Timothy ; Chandra, Sunandana ; Chae, Young K wang ; Cristofanilli, Massimo ; Giles, Francis J. / Is Personalized Medicine Here?. In: Oncology (Williston Park, N.Y.). 2016 ; Vol. 30, No. 4.
@article{05caa4ad82b24223893a38489e3d69da,
title = "Is Personalized Medicine Here?",
abstract = "Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of cancer genomics is reshaping the drug development process, from drug discovery to novel designs of clinical trials. It is also exposing the critical importance of rigorous validation of molecular diagnostics platforms, such as the use of whole-exome sequencing and patient-derived xenografts, which may eventually be utilized to guide treatment decisions and may ultimately enable the true practice of personalized oncology. This review describes the achievements in therapeutic and molecular diagnostics, details evolving molecular platforms, and highlights the challenges for the translation of these developments to daily clinical practice.",
author = "Carneiro, {Benedito A.} and Ricardo Costa and Timothy Taxter and Sunandana Chandra and Chae, {Young K wang} and Massimo Cristofanilli and Giles, {Francis J.}",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "30",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

Carneiro, BA, Costa, R, Taxter, T, Chandra, S, Chae, YKW, Cristofanilli, M & Giles, FJ 2016, 'Is Personalized Medicine Here?', Oncology (Williston Park, N.Y.), vol. 30, no. 4.

Is Personalized Medicine Here? / Carneiro, Benedito A.; Costa, Ricardo; Taxter, Timothy; Chandra, Sunandana; Chae, Young K wang; Cristofanilli, Massimo; Giles, Francis J.

In: Oncology (Williston Park, N.Y.), Vol. 30, No. 4, 01.04.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Is Personalized Medicine Here?

AU - Carneiro, Benedito A.

AU - Costa, Ricardo

AU - Taxter, Timothy

AU - Chandra, Sunandana

AU - Chae, Young K wang

AU - Cristofanilli, Massimo

AU - Giles, Francis J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of cancer genomics is reshaping the drug development process, from drug discovery to novel designs of clinical trials. It is also exposing the critical importance of rigorous validation of molecular diagnostics platforms, such as the use of whole-exome sequencing and patient-derived xenografts, which may eventually be utilized to guide treatment decisions and may ultimately enable the true practice of personalized oncology. This review describes the achievements in therapeutic and molecular diagnostics, details evolving molecular platforms, and highlights the challenges for the translation of these developments to daily clinical practice.

AB - Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of cancer genomics is reshaping the drug development process, from drug discovery to novel designs of clinical trials. It is also exposing the critical importance of rigorous validation of molecular diagnostics platforms, such as the use of whole-exome sequencing and patient-derived xenografts, which may eventually be utilized to guide treatment decisions and may ultimately enable the true practice of personalized oncology. This review describes the achievements in therapeutic and molecular diagnostics, details evolving molecular platforms, and highlights the challenges for the translation of these developments to daily clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84973438875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973438875&partnerID=8YFLogxK

M3 - Review article

VL - 30

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 4

ER -